Orthocell see 89% of patients return to work pain-free

Company News

by Rachael Jones

Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per cent of patients return to work and recreation pain-free.

A review of patients who completed the trial confirmed all patients achieved a successful tendon repair with no revision surgeries reported.

CelGro® strengthens rotator cuff tendon repair in the shoulder.

No revision surgeries were reported at two years after CelGro® tendon regeneration surgery.

It's now shown to improve nerve, tendon and bone repair.

Shares in Orthocell (ASX:OCC) are trading 10.13 per cent higher at $0.43.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.